Sharpunkha has been reported to possess anti-hyperlipidemic and hepatoprotective activity. In an experimental study, it brought about significant reduction in serum aspartate aminotransaminase, alanine aminotransaminase, gamma glutamyl transpeptidase, alkaline phosphatase, total bilirubin, and liver MDA levels, and significant improvement in liver glutathione, when compared with thioacetamide damaged rats. Kakamachi has been reported to possess hepato-protective, anti-tumor, cytostatic, anti-convulsant, anti-ulcerogenic, anti-inflammatory effects. In addition, it is diuretic, protects kidneys, and is anti-edematous. In an experimental study, its ethanol extract showed remarkable hepatoprotective activity against CCI4 -induced hepatic damage in rats.
Bhumi-amalaki has been reported to protect the liver and reduce elevated SGPT, alkaline phosphatase (APT), and lipid peroxidation; and restore superoxidase dismutase (SOD), catalase (CAT), and glutathione-S-transferase (GST) to almost normal levels. It is effective against Hepatitis B and HIV. It lowers raised total & LDL cholesterol and triglycerides, raised blood sugar, raised blood pressure, raised serum uric acid, and eliminates / dissolves urinary calculi. In a preliminary study, carriers of hepatitis B virus were treated with a Bhumi-amalaki for 30 days. 22 of 37 (59%) treated patients had lost hepatitis B surface antigen when tested 15-20 days after the end of the treatment compared with only 1 of 23 (4%) placebo-treated controls. Some subjects have been followed for up to 9 months. In no case has the surface antigen returned. Clinical observation revealed few or no toxic effects. In another study, it was found to suppress HBV mRNA transcription in vitro and exhibits therapeutic potential in chronic HBV carriers. Analysis in HuH-7 cells with transfected plasmids using a luciferase reporter showed that Bhumi-amalaki specifically inhibited HBV enhancer I activity. Exposure to Bhumi-amalaki inhibited C/EBPα- and β-mediated up-regulation of HBV enhancer I activity in a dose-dependent manner, whereas HNF-3α- and β-mediated up-regulation of HBV enhancer I was unaffected. LIVIE Tablet helps in keeping the blood thin by prolonging the Prothrombin Time. It should, therefore, be avoided while taking anticoagulant medicines.
Weight 60 g
INDICATION
LIVER: LIVIE Tablet is mainly used for treating liver diseases like jaundice, Hepatitis A/B/C, Liver damage caused by alocohol / allopathic drugs, fatty infiltration of (collection of fat in) the liver, abnormal liver enzymes (SGOT, SGPT, Alkaline phosphatase, etc.).
GALL BLADDER: LIVIE Tablet may help in the gall bladder stones, especially, in the early stages (sand / sludge).
KIDNEYS: LIVIE Tablet is quite useful in several diseases of the kidneys, especially, when the blood urea and creatinine rise due to some reversible damage (abnormality) in the kidneys.
It helps dissolve urinary stones, especially when new and not-so-large-in-size. LIVIE Tablet is useful when there occurs abnormal collection of water (edema) in the body due to liver or kidney diseases.
SPLEEN: LIVIE Tablet is useful when the spleen is enlarged (due to non-fatal causes). PANCREAS: LIVIE Tablet is useful in the swelling in the pancreas (pancreatitis).
METABOLIC DISEASES: LIVIE Tablet is useful as a supportive treatment for the management of diseases occurring due to disturbed metabolism, like obesity (overweight), diabetes, gout, high blood cholesterol and triglycerides, high blood pressure, overactive thyroid (hyperthyroidism).
HOW TO USE Adults: Initial dose – 1 tab thrice a day. Maintenance dose -1 tab once / twice a day. Children (6-9 yrs): A tab twice / thrice a day. To be swallowed with water, just after / within meals. For children, crush and administer with honey, water, milk, fruit juice.
